Evidence map›Paper›PMID 38092551›Full record

ArticleClinical and molecular hepatology2024

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.

Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H Nguyen, Jaw-Town Lin and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Virological markers for clinical trials in chronic viral hepatitis.JHEP reports : innovation in hepatology · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ying-Nan TsaiDivision of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
Jia-Ling WuDepartment of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan.
Cheng-Hao TsengDivision of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
Tzu-Haw ChenDivision of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Yi-Ling WuDivision of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Chieh-Chang ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yu-Jen FangDepartment of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Tzeng-Huey YangDivision of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Yilan, Taiwan.
Mindie H NguyenDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
Jaw-Town LinDivision of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Yao-Chun HsuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.

Funding

E-Da Hospital EDCHP111007National Science and Technology Council in Taiwan 110-2314-B-214 -006 -MY3Tomorrow Medical Foundation 112-1
6 · The paper itself

Abstract

BACKGROUND/

aimsFinite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR).

methodsThis retrospective multicenter analysis enrolled adults with CHB who were prospectively monitored after discontinuing entecavir or tenofovir with negative HBeAg and undetectable HBV DNA at the end of treatment (EOT). Patients with cirrhosis or malignancy were excluded. CR was defined as serum alanine aminotransferase > two times the upper limit of normal with recurrent viremia. We applied time-dependent Cox proportional hazard models to clarify the association between HBcrAg levels and subsequent CR.

resultsThe cohort included 203 patients (median age, 49.8 years; 76.8% male; 60.6% entecavir) who had been treated for a median of 36.9 months (interquartile range [IQR], 36.5-40.1). During a median post-treatment follow-up of 31.7 months (IQR, 16.7-67.1), CR occurred in 104 patients with a 5-year cumulative incidence of 54.8% (95% confidence interval [CI], 47.1-62.4%). Time-varying HBcrAg level was a significant risk factor for subsequent CR (adjusted hazard ratio [aHR], 1.53 per log U/mL; 95% CI, 1.12-2.08) with adjustment for EOT HBsAg, EOT anti-HBe, EOT HBcrAg and time-varying HBsAg. During follow-up, HBcrAg <1,000 U/mL predicted a lower risk of CR (aHR, 0.41; 95% CI, 0.21-0.81).

conclusionDynamic measurement of HBcrAg after NA cessation is predictive of subsequent CR and may be useful to guide post-treatment monitoring.

Indexed as

Hepatitis B, ChronicHepatitis B Core AntigensAdultAntiviral AgentsDNA, ViralFemaleHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansMaleMiddle AgedRecurrenceAntiviral AgentsDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensAntiviral treatmentChronic hepatitis BFinite nucleos(t)ide analog therapyHepatitis B core-related antigen

Identifiers

PMID38092551
PMCPMC10776300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.